CohBar Balance Sheet Health

Financial Health criteria checks 4/6

CohBar has a total shareholder equity of $9.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $12.5M and $3.0M respectively.

Key information

Debt to equity ratio

US$0

Debt

Interest coverage ratio	n/a
Cash	US$12.31m
Equity	US$9.50m
Total liabilities	US$3.00m
Total assets	US$12.51m

Recent financial health updates

Here's Why We're Watching CohBar's (NASDAQ:CWBR) Cash Burn Situation

Jun 13

Recent updates

Financial Position Analysis

Short Term Liabilities: CWBR's short term assets ($12.5M) exceed its short term liabilities ($3.0M).

Long Term Liabilities: CWBR has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: CWBR is debt free.

Reducing Debt: CWBR has no debt compared to 5 years ago when its debt to equity ratio was 11.2%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if CWBR has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CWBR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

CohBar Balance Sheet Health

Financial Health criteria checks 4/6

Key information

Recent financial health updates

CohBar Expects the Trading in its Common Stock to be Suspended Upon the Opening of Business on November 29, 2023 and Nasdaq to File Form 25-NSE with the SEC to Formally Delist CohBar's Common Stock

Here's Why We're Watching CohBar's (NASDAQ:CWBR) Cash Burn Situation

CohBar Announces Extension of Nasdaq Compliance Period

Recent updates

CohBar, Inc.(OTCPK:CWBR) dropped from S&P TMI Index

CohBar, Inc.(OTCPK:CWBR) dropped from NASDAQ Composite Index

CohBar Expects the Trading in its Common Stock to be Suspended Upon the Opening of Business on November 29, 2023 and Nasdaq to File Form 25-NSE with the SEC to Formally Delist CohBar's Common Stock

Morphogenesis, Inc. cancelled the acquisition of CohBar, Inc. (NasdaqCM:CWBR) in a reverse merger transaction.

New major risk - Share price stability

Morphogenesis, Inc. and Cohbar, Inc. Announce Positive Results from Phase 1B Trial of Ifx-Hu2.0, A Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Morphogenesis, Inc. entered into a definitive agreement to acquire CohBar, Inc. (NasdaqCM:CWBR) for approximately $130 million in a reverse merger transaction.

High number of new and inexperienced directors

CohBar, Inc. to Report Q3, 2022 Results on Nov 08, 2022

CohBar stock gains on 1-for-30 reverse stock split

CohBar, Inc. to Report Q2, 2022 Results on Aug 15, 2022

CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

Here's Why We're Watching CohBar's (NASDAQ:CWBR) Cash Burn Situation

CohBar Announces Extension of Nasdaq Compliance Period

CohBar, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$2.17

High number of new and inexperienced directors

CohBar, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target decreased to US$5.63

Independent Director recently bought US$96k worth of stock

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity

High number of new directors

CohBar, Inc. Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

CohBar, Inc.(NasdaqCM:CWBR) dropped from Russell 3000E Index

CEO & Director Steven Engle has left the company

Price target decreased to US$6.10

CohBar appoints Joseph Sarret as CEO and Director

CohBar, Inc. Announces the Selection of CB5138-3

New 90-day high: US$1.65

CohBar, Inc. Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS

CohBar collaborates with NIAID for CB5064 analogs in COVID-19-related ARDS

New 90-day high: US$1.54

CohBar, Inc. Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome Model

New 90-day high: US$1.21

CohBar EPS in-line

CohBar, Inc. to Report Q3, 2020 Results on Nov 16, 2020

CohBar (CWBR) Investor Presentation - Slideshow

CohBar, Inc. Announces New Preclinical Data Demonstrating That Combination of A Cb5138 Analog with nintedanib

CohBar, Inc. has completed a Composite Units Offering in the amount of $15.006 million.

New 90-day low - US$1.36

CohBar, Inc. to Report Q2, 2020 Results on Aug 13, 2020

New 90-day low - US$1.46

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Cash Runway Analysis

Discover healthy companies